Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitish vs Henry Meds

Fitish
Graded #342

Lower grade

vs+16.4
Henry Meds
Graded #48

Higher grade

The verdict

Henry Meds takes it — 77.3/100 to 60.9/100.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Henry's low monthly equivalents come with a full year paid upfront, so it is a poor fit for someone shopping for a short trial.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHenry Meds +21
51
72
Dose & formulationHenry Meds +5
75
80
Clinical oversightHenry Meds +25
55
80
Labs & monitoringHenry Meds +26
52
78
FulfillmentFitish +5
83
78
Contract termsHenry Meds +23
55
78
Fitish · left barHenry Meds · right bar

The numbers

MetricFitishHenry Meds
WeighScore60.9/10077.3/100
GradeCC+
Scorecard rank#342#48
Semaglutide$219/mo (compounded)$197/mo (injectable; 12-month plan paid upfront in full, $2,364)
Tirzepatide$339/mo (compounded)$234/mo (compounded oral tablets; 12-month plan paid upfront in full, $2,808)
CoverageAll 50 statesMulti-state
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Fitish

Graded #342 · C

FDAWarning letter issued to FITISH in June 2026. See the FDA warning-letter database.

Strengths

  • LegitScript certified
  • Ships to all US states
  • Price includes consult, shipping, and medication
  • Injectable and oral tablet formats
  • Microdosing option available

Where it loses points

  • No physical address disclosed
  • Broader wellness/beauty brand — GLP-1 is one product line
  • Compounded only — no brand-name options
  • FDA issued FITISH a warning letter in June 2026; the letter is public in FDA's warning-letter database
Henry Meds

Graded #48 · C+

Strengths

  • Published plan prices identify their upfront-payment requirement
  • Medication, provider access, applicable supplies and shipping included if prescribed
  • Compounded injectable semaglutide and oral options listed

Where it loses points

  • The $197 semaglutide headline requires $2,364 upfront, not monthly payments
  • The listed $234 tirzepatide offer is oral compounded medication, not an injectable quote
  • Multi-month balances may remain payable after cancellation; medical-discontinuation refunds require documentation and approval, and dispensed medication is excluded

Also worth a look

Another provider to compare: CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard